Article Category: CKD

AI-assisted summary disclosure: This educational article was prepared with AI-assisted drafting and editorial review. It is a concise synthesis rather than a systematic review or clinical advice. Readers should consult the original publication, current guidelines, and qualified clinicians before applying findings.

Review window: 8–15 August 2026 (GMT+3)
Prepared for: NephroHub
Scope: JASN, AJKD, NEJM, The Lancet, NDT, Kidney International, CJASN, Nature Reviews Nephrology, and BMC Nephrology.

Editorial method: This is a selective clinical roundup, not a systematic review. Articles were included only when their publication date and source record could be verified during the review window. Summaries are concise, evidence-calibrated, and link directly to the original publication or its PubMed record.

At a glance

Measure	This review
Review window	8–15 August 2026
Featured articles	6
Journals represented in featured articles	4
Monitored journals	9
Highest-priority themes	Dialysis modality, diabetic CKD, IgA nephropathy, transplant glomerulopathy, and CKD prevention

This week’s strongest clinically relevant material is concentrated in JASN, NDT, AJKD, and BMC Nephrology. A direct, date-limited search did not identify a new PubMed-indexed Kidney International item for this window. NEJM, The Lancet, CJASN, and Nature Reviews Nephrology were monitored; relevant non-core nephrology or commentary items were not included in this focused practice roundup.

Featured articles

Priority	Journal	Article	Topics	Why it matters
1	JASN	Hemodiafiltration versus high-flux hemodialysis and mortality	Dialysis	Large multinational target-trial emulation showing an association between sustained high-volume HDF and lower mortality.
2	BMC Nephrology	BAFF/APRIL inhibitors in IgA nephropathy	Glomerular Disease	Network meta-analysis supports substantial proteinuria reduction, but long-term kidney-failure benefit remains unproven.
3	NDT	RAS inhibition in dialysis-dependent HFrEF	Dialysis CKD	Meta-analysis suggests potential benefit, but evidence is predominantly observational.
4	NDT	Recurrent C3 glomerulopathy after transplantation	Glomerular Disease Transplantation	Practical surveillance-first framework for a difficult, high-risk transplant complication.
5	NDT	Individualising therapy in diabetic CKD	CKD	Clear reminder to combine proven therapies with monitoring and lifestyle management, without overclaiming evidence for combinations.
6	AJKD	Blood pressure, kidney function, and kidney mortality	CKD Hypertension	Large cohort reinforces blood-pressure control as a CKD-prevention priority.

1. Hemodiafiltration versus high-flux hemodialysis and mortality

Source: Strippoli GFM, Tripepi G, Canaud B, et al. Journal of the American Society of Nephrology. Published online 13 August 2026. DOI: 10.1681/ASN.0000001225.

Concise AI summary. In a multinational, registry-based target-trial emulation of 19,539 eligible in-centre dialysis patients, sustained high-volume post-dilution hemodiafiltration (HDF) was associated with lower all-cause mortality than high-flux haemodialysis (hazard ratio 0.72; 95% CI 0.67–0.77). Two-year weighted mortality was 20.6% with HDF and 22.3% with high-flux HD, an absolute difference of 1.7 percentage points. [1]

Clinical relevance: High. The result strengthens the rationale for considering high-volume HDF where infrastructure, vascular access, water quality, and local expertise permit. However, it is an observational emulation rather than a randomised trial; selection and centre-level factors cannot be fully excluded.

2. BAFF/APRIL-pathway inhibition in IgA nephropathy

Source: Mansour N, Elbarody RMF, Kamel AM. BMC Nephrology. Published 11 August 2026. DOI: 10.1186/s12882-026-05267-4.

Concise AI summary. This systematic review and network meta-analysis included seven placebo-controlled trials involving 1,590 adults with biopsy-proven IgA nephropathy. BAFF/APRIL-pathway inhibitors (telitacicept, atacicept, and sibeprenlimab) reduced proteinuria versus placebo (standardised mean change −0.73; 95% CI −0.88 to −0.58) and showed a small short-term difference in eGFR favouring active treatment. Injection-site reactions were more frequent, whereas overall adverse-event rates were not higher. [2]

Clinical relevance: High. The analysis supports the biologic and antiproteinuric activity of this drug class. It should not yet be interpreted as proof of durable protection from kidney failure; long-term trials with hard renal outcomes remain necessary.

3. Renin–angiotensin system inhibition in dialysis-dependent HFrEF

Source: Sritharan A, Marchetti M, Antiochos P, et al. Nephrology Dialysis Transplantation. Published online 12 August 2026. DOI: 10.1093/ndt/gfag184.

Concise AI summary. This systematic review and meta-analysis assessed RAS inhibition in dialysis-dependent patients with heart failure with reduced ejection fraction. ARNI use was associated with lower all-cause mortality than non-ARNI regimens (pooled HR 0.78; 95% CI 0.71–0.87); ACE inhibitor/ARB use was also associated with lower all-cause mortality (HR 0.76; 95% CI 0.68–0.84) and cardiovascular mortality (HR 0.62; 95% CI 0.54–0.71). [3]

Clinical relevance: Moderate. This fills an evidence gap in a high-risk population but relies largely on observational studies. It supports careful, individualised use with monitoring for blood pressure, potassium, and residual kidney function rather than a universal prescribing mandate.

4. Management of recurrent C3 glomerulopathy after kidney transplantation

Source: Trujillo H, Cavero T, Moran SM, et al. Nephrology Dialysis Transplantation. Published online 11 August 2026. DOI: 10.1093/ndt/gfag183.

Concise AI summary. This practical review highlights that C3 glomerulopathy frequently recurs early after transplantation, sometimes before clinical manifestations are apparent. No validated biomarkers reliably predict recurrence and preventive strategies remain unproven. The authors favour a surveillance-driven approach, including consideration of protocol biopsies and evolving use of proximal complement inhibitors. [4]

Clinical relevance: High for transplant centres. The article is a useful framework for pre-transplant counselling, post-transplant monitoring, and specialist discussion of complement-directed therapy. It is not a replacement for individualised multidisciplinary management.

5. Individualising therapy for CKD associated with diabetes

Source: Zhang Z, Li L, Yang M, et al. Nephrology Dialysis Transplantation. Published online 8 August 2026. DOI: 10.1093/ndt/gfag179.

Concise AI summary. This review integrates RAS inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone with blood-pressure management, individualised glycaemic goals, diet, exercise, weight management, and smoking cessation. It notes that no head-to-head trial has compared all drug classes and that phase 3 evidence for specific multi-class combinations improving hard outcomes beyond well-selected monotherapy is still incomplete. [5]

Clinical relevance: High. The central message is practical: layer proven treatments according to albuminuria, eGFR, comorbidities, tolerability, and monitoring capacity, while avoiding automatic polypharmacy. It is a review, not new comparative trial evidence.

6. Blood pressure, kidney function, and kidney mortality among Mexican adults

Source: Zhu D, Kuri-Morales P, Wade R, et al. American Journal of Kidney Diseases. Published online 13 August 2026. DOI: 10.1053/j.ajkd.2026.05.019.

Concise AI summary. In a prospective cohort of 133,470 Mexican adults without baseline CKD, each 20-mmHg lower systolic blood pressure was associated with lower kidney-failure mortality (HR 0.76; 95% CI 0.69–0.84). In a re-evaluated subset, lower baseline systolic BP was also associated with lower odds of CKD and albuminuria. [6]

Clinical relevance: High. This large cohort reinforces BP control as a key population-level CKD-prevention measure, including in settings with a high burden of undiagnosed hypertension. The associations are observational and should not be read as defining a personalised treatment target.

Practice takeaways

Theme	Evidence-calibrated takeaway
Dialysis modality	High-volume HDF is associated with lower mortality in a large observational emulation; programme-level feasibility and patient-specific factors still matter. [1]
IgA nephropathy	BAFF/APRIL inhibition is an important emerging targeted approach because of consistent proteinuria lowering; durable kidney-outcome evidence is still developing. [2]
Dialysis with HFrEF	RAS blockade may be beneficial, but the current meta-analytic signal is primarily observational and requires careful safety monitoring. [3]
Kidney transplantation	For C3G, prioritise recurrence surveillance and early specialist review; proven prophylaxis is lacking. [4]
Diabetic CKD	Use an individualised, monitored, layered strategy rather than assuming every multi-drug combination has established hard-outcome benefit. [5]
CKD prevention	Sustained BP control remains central to preventing albuminuria, CKD, and kidney-failure mortality at population level. [6]

References

Educational notice: This review is intended for medical education and website content. It does not replace the original article, local protocols, professional guidelines, or patient-specific clinical judgement.

Week of October 29 – November 2, 2025

Article 1: Combination Therapy for Diabetic Kidney Disease

Publication Details

•Title: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

•Journal: New England Journal of Medicine (IF: 176.1)

•Publication Date: October 29, 2025

•Volume/Issue: Vol. 393 No. 17

•DOI: 10.1056/NEJMc2513088

•Source URL: https://www.nejm.org/doi/full/10.1056/NEJMc2513088

•Article Type: Correspondence

Summary

Key Findings: The CONFIDENCE trial demonstrated that combination therapy with finerenone (a mineralocorticoid receptor antagonist) and empagliflozin (an SGLT2 inhibitor) produces significantly greater reduction in urinary albumin-to-creatinine ratio compared to either medication alone in patients with chronic kidney disease and type 2 diabetes.

Clinical Impact: This combination represents a potential paradigm shift in diabetic kidney disease management, offering enhanced nephroprotection through complementary mechanisms. The dual approach targets both inflammatory pathways (finerenone) and glucose-sodium reabsorption (empagliflozin).

Clinical Relevance: High – Directly applicable to millions of diabetic CKD patients worldwide, potentially becoming new standard of care.

Article 2: Precision Dialysis Prediction Model

Publication Details

•Title: A prescription-based model for predicting post-hemodialysis urea and electrolytes: a real-world validation study in acute hemodialysis

•Journal: BMC Nephrology (IF: 2.3)

•Publication Date: October 27, 2025

•DOI: 10.1186/s12882-025-04456-x

•Source URL: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04456-x

•Article Type: Research Article

Summary

Key Findings: Researchers developed and validated a prescription-based model that accurately predicts post-hemodialysis blood urea nitrogen and electrolyte levels using only treatment parameters. The model showed strong correlations (r=0.96 for BUN, r=0.96 for sodium, r=0.84 for potassium) and was integrated into a free web application called “Adequator app®.”

Clinical Impact: This tool enables precise dialysis prescription optimization, particularly valuable for high-risk patients prone to dialysis disequilibrium syndrome or severe electrolyte abnormalities. The 92% success rate in achieving target BUN reduction without neurological complications demonstrates significant safety improvements.

Clinical Relevance: High – Essential for acute dialysis settings and intensive care units managing critically ill patients.

Article 3: Global Kidney Health Policy Framework

Publication Details

•Title: Strategic rebalancing of kidney-related investments is key to implementing the WHO kidney health resolution

•Journal: Nature Reviews Nephrology (IF: 31.8)

•Publication Date: October 31, 2025

•DOI: 10.1038/s41581-025-01017-1

•Source URL: https://www.nature.com/articles/s41581-025-01017-1

•Article Type: Comment

Summary

Key Findings: Following the World Health Organization’s historic kidney health resolution, this analysis outlines strategic investment approaches needed for implementation. The authors emphasize embedding kidney health interventions into primary care and community-based non-communicable disease platforms to improve sustainability and equity.

Clinical Impact: Provides a roadmap for healthcare systems worldwide to integrate kidney care into existing infrastructure, potentially improving access to care for underserved populations while optimizing resource allocation across the care continuum.

Clinical Relevance: High – Critical for healthcare policy makers and system administrators planning kidney care delivery models.

Article 4: Gene Therapy Breakthrough for Alport Syndrome

Publication Details

•Title: Mouse Alport podocytes are susceptible to AAV9

•Journal: Kidney International (IF: 19.9)

•Publication Date: November 1, 2025

•Source URL: https://www.kidney-international.org/article/S0085-2538(25)00854-3/fulltext

•Article Type: Research Article

Summary

Key Findings: This study demonstrates that adeno-associated virus serotype 9 (AAV9) can effectively target podocytes in Alport syndrome mouse models. The research builds on previous work showing AAV2/9 with podocin expression prevented kidney disease progression in proteinuric mice, suggesting potential for human gene therapy applications.

Clinical Impact: Represents a significant advancement in gene therapy approaches for hereditary nephritis. The successful targeting of podocytes opens new therapeutic avenues for Alport syndrome, a progressive genetic kidney disease with limited treatment options.

Clinical Relevance: Moderate – Important for rare disease specialists and patients with hereditary nephritis, though clinical translation requires further development.

Article 5: Drug-Induced Acute Kidney Injury

Publication Details

•Title: BCR-ABL tyrosine kinase inhibitors associated acute kidney injury

•Journal: BMC Nephrology (IF: 2.3)

•Publication Date: October 2025

•Source URL: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-025-04539-9

•Article Type: Research Article

Summary

Key Findings: This study examines acute kidney injury associated with BCR-ABL tyrosine kinase inhibitors used in chronic myeloid leukemia treatment. With CML incidence at approximately 2 per 100,000 globally and 9,560 new US cases projected for 2025, understanding nephrotoxicity patterns is crucial for patient management.

Clinical Impact: Provides essential safety data for oncologists and nephrologists managing CML patients. Early recognition and management of TKI-associated AKI can prevent progression to chronic kidney disease and optimize cancer treatment outcomes.

Clinical Relevance: Moderate – Important for oncology-nephrology collaboration and CML patient monitoring protocols.

Article 6: Cardiovascular Biomarkers in CKD

Publication Details

•Title: Cardiac Biomarkers in Chronic Kidney Disease: Signal or Noise?

•Journal: Clinical Journal of the American Society of Nephrology (IF: 8.2)

•Publication Date: October 31, 2025

•Source URL: https://journals.lww.com/cjasn/toc/publishahead

•Article Type: Research Article

Summary

Key Findings: This analysis examines the clinical utility and interpretation challenges of cardiac biomarkers in chronic kidney disease patients. The study addresses the complex relationship between kidney function decline and cardiovascular risk assessment, particularly regarding biomarker elevation patterns.

Clinical Impact: Clarifies the diagnostic and prognostic value of cardiac biomarkers in CKD populations, helping clinicians distinguish between kidney-related biomarker elevation and true cardiovascular events. This is crucial given that cardiovascular disease remains the leading cause of death in CKD patients.

Clinical Relevance: High – Essential for cardio-nephrology practice and risk stratification in CKD patients.

Article 7: Global Healthcare Workforce Solutions

Publication Details

•Title: Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis

•Journal: Kidney International Reports (IF: 4.2)

•Publication Date: October 4, 2025

•Source URL: https://www.kireports.org/inpress

•Article Type: Review Article

Summary

Key Findings: This comprehensive review examines how nonphysician health workers can be integrated into kidney care delivery to address the global chronic kidney disease crisis. The analysis covers training protocols, scope of practice, and successful implementation models from various healthcare systems.

Clinical Impact: Offers practical solutions for healthcare systems facing nephrology workforce shortages. The integration of trained nonphysician providers can significantly expand access to kidney care, particularly in underserved regions and resource-limited settings.

Clinical Relevance: High – Critical for healthcare administrators and policy makers addressing nephrology workforce challenges globally.

📋 Key Takeaways for Clinicians

Evidence-Based Practice Updates:

1.Combination therapy shows superior outcomes in diabetic CKD

2.Predictive modeling improves dialysis safety and efficacy

3.Biomarker interpretation requires CKD-specific considerations

4.Workforce expansion through nonphysician providers is feasible

Quality Improvement Opportunities:

1.Standardize combination therapy protocols for diabetic CKD

2.Implement prediction tools in acute dialysis settings

3.Develop multidisciplinary care pathways

4.Expand access through innovative care delivery models

Research and Development Priorities:

1.Long-term outcomes of combination therapies

2.Implementation science for WHO resolution

3.Gene therapy translation for hereditary diseases

4.Digital health integration effectiveness

Kidney-HUB Nephrology Research Review Team

Review Date: November 2, 2025

October 21-25, 2025

New England Journal of Medicine (IF: 176.1)

Featured Article: Disparities in Kidney Disease and the Race-Neutral eGFR

Published: October 25, 2025
Authors: Angelica Bocour, M.P.H., Erin Lewis, M.D., Silas Lee, M.S., Leo G. Eisenstein, M.D.
Type: Perspective Article

Key Findings:
The race-adjusted estimated glomerular filtration rate (eGFR) has historically reduced Black patients’ access to kidney transplants. NYC Health+Hospitals is conducting a comprehensive study examining the effects of implementing race-neutral eGFR algorithms across their public hospital system.

Clinical Impact:
This research addresses a critical health equity issue in nephrology, potentially influencing how kidney function is assessed nationwide and improving transplant access for underserved populations.

Clinical Relevance: High – Directly impacts clinical decision-making and health equity in kidney care

BMC Nephrology (IF: 2.3)

1. Association of Incident Dialysis Modality with Patient Survival

Published: October 24, 2025
Authors: Luca Nardelli, Matteo Passerini, Dalia Zubidat, et al.
Type: Systematic Review and Meta-analysis

Key Findings:
Comprehensive analysis comparing peritoneal dialysis (PD) versus hemodialysis (HD) outcomes shows nuanced survival differences based on patient characteristics and comorbidities. The choice of dialysis modality significantly impacts long-term patient outcomes.

Clinical Impact:
Provides evidence-based guidance for clinicians and patients making dialysis modality decisions, emphasizing the importance of individualized treatment approaches.

Clinical Relevance: High – Essential for dialysis treatment planning

2. Chronic Kidney Disease of Unknown Etiology: Real-World Study

Published: October 24, 2025
Authors: Joshua Storrar, Sayyid Raza, Ivona Baricevic-Jones, et al.
Type: Research Article

Key Findings:
Analysis of CKD cases where conventional diagnostic workup fails to identify etiology. The study identifies patterns and potential diagnostic approaches for these challenging cases, which represent a significant portion of CKD patients.

Clinical Impact:
Improves diagnostic strategies for unexplained CKD cases and highlights the need for advanced diagnostic techniques in nephrology practice.

Clinical Relevance: Moderate – Important for diagnostic workup protocols

3. Iptacopan in C5 Blockade Refractory Atypical Hemolytic Uremic Syndrome

Published: October 24, 2025
Authors: Matthew D. Nguyen, Stefan Ciurea, Sheetal Desai, et al.
Type: Case Report

Key Findings:
First reported case of factor B inhibition using iptacopan in a patient with aHUS refractory to C5 blockade, associated with Castleman’s disease. The treatment showed promising results in this complex case.

Clinical Impact:
Expands therapeutic options for treatment-resistant aHUS cases and demonstrates the potential of alternative complement pathway targeting.

Clinical Relevance: Moderate – Relevant for rare disease management

4. Heat Stress and Serum Creatinine Changes in CKD Patients

Published: October 22, 2025
Authors: Namrata Rao, Ahmad Shakeb, Abhilash Chandra, et al.
Type: Research Article

Key Findings:
Study from Northern India demonstrates that heat wave conditions significantly impact kidney function in CKD patients, with heat stress symptoms predicting serum creatinine changes. This research is particularly relevant given increasing global temperatures.

Clinical Impact:
Highlights the importance of climate considerations in CKD management and the need for protective strategies during extreme weather events.

Clinical Relevance: High – Increasingly important with climate change

Kidney International (IF: 19.9)

1. New Potential Therapeutic Targets in Metabolic Disorder-Associated Kidney Disease

Published: October 23, 2025
Authors: Li et al.
Type: Mini Review

Key Findings:
Comprehensive review of emerging therapeutic targets for metabolic syndrome-related kidney disease, including novel pathways involved in diabetic kidney disease progression and potential intervention points.

Clinical Impact:
Identifies future directions for drug development in diabetic kidney disease, potentially leading to new treatment options for this growing patient population.

Clinical Relevance: High – Addresses major cause of CKD globally

2. Optimizing Cardiovascular Outcomes in Pediatric Dialysis

Published: October 25, 2025
Authors: Shroff et al.
Type: Mini Review

Key Findings:
Evidence-based strategies for managing cardiovascular risk in children on dialysis, addressing the unique challenges of pediatric kidney failure and long-term cardiovascular health.

Clinical Impact:
Provides guidance for improving long-term outcomes in pediatric dialysis patients, focusing on cardiovascular risk reduction strategies.

Clinical Relevance: High – Critical for pediatric nephrology practice

Nature Portfolio Journals

1. Inhibition of PGK1 Ameliorates Acute Kidney Injury

Published: October 24, 2025
Journal: Nature Communications
Type: Basic Research

Key Findings:
Novel mechanism discovered where PGK1 interaction with PKM2 contributes to renal injury through phosphorylation, dimer formation, and nuclear translocation. Targeting this pathway shows therapeutic potential for AKI.

Clinical Impact:
Identifies a new therapeutic target for acute kidney injury treatment, potentially leading to novel interventions for this common and serious condition.

Clinical Relevance: High – AKI affects millions globally

2. Exosomal miR-122-5p Ameliorates Renal Interstitial Fibrosis

Published: October 21, 2025
Journal: Cell Death & Disease
Type: Basic Research

Key Findings:
Tubular cell-derived exosomal miR-122-5p regulates fibroblasts and reduces renal interstitial fibrosis, offering a novel approach to treating kidney fibrosis through extracellular vesicle therapy.

Clinical Impact:
Opens new avenues for treating kidney fibrosis, a major cause of progressive kidney disease, through targeted exosome-based therapies.

Clinical Relevance: Moderate – Important for fibrosis research

📊 Clinical Practice Guidelines and Updates

KDIGO 2025 Guidelines Released

1. IgA Nephropathy and IgA Vasculitis Management

Status: Recently Published
Scope: Updated guidelines covering new developments in IgAN assessment and therapy

Key Updates:

New risk stratification approaches
Updated treatment algorithms
Evidence-based therapeutic recommendations
Pediatric considerations

Clinical Impact:
Provides standardized, evidence-based approach to managing the most common primary glomerulonephritis worldwide.

2. Nephrotic Syndrome in Children

Status: Recently Updated
Scope: Comprehensive guidance for pediatric nephrotic syndrome management

Key Updates:

Steroid-sensitive and steroid-resistant treatment protocols
Long-term management strategies
Quality of life considerations
Family-centered care approaches

📋 Key Takeaways for Clinicians

High Priority

Health Equity: Review and address potential biases in kidney function assessment and treatment access
Climate Adaptation: Develop strategies for protecting kidney patients during extreme weather events
Personalized Care: Emphasize individualized treatment approaches based on patient characteristics and preferences

Moderate Priority

Diagnostic Innovation: Stay informed about advances in diagnosing unexplained CKD
Rare Disease Management: Maintain awareness of novel treatments for complex kidney diseases
Pediatric Considerations: Implement cardiovascular risk reduction strategies in pediatric patients

Research and Development

Therapeutic Targets: Monitor development of treatments targeting PGK1, exosomal therapies, and metabolic pathways
Clinical Trials: Consider patient eligibility for trials investigating novel AKI and fibrosis treatments
Guideline Implementation: Prepare for implementation of updated KDIGO guidelines

This weekly review compiled from major nephrology journals and research databases. Next review scheduled for November 1, 2025.

Prepared by: Kidney-HUB Nephrology Research Review Team
Date: October 25, 2025
Contact: For questions or additional information about specific studies mentioned in this review

The kidneys are essential organs that filter waste and extra fluids from the blood, helping the body stay bKeeping your kidneys healthy is one of the smartest long-term investments you can make in your body’s future. These two bean-shaped organs quietly filter about 180 liters of blood every day, removing waste, balancing electrolytes, and regulating blood pressure. When they’re unhappy, the whole body feels it. Here’s how to keep them content and working at their best—based on evidence from reputable medical sources such as the National Kidney Foundation (NKF), Centers for Disease Control and Prevention (CDC), and World Health Organization (WHO):

1. Stay Hydrated — but Don’t Overdo It

Water helps the kidneys clear sodium and toxins. For most adults, 2–3 liters per day (around 8–10 cups) is ideal, but this varies depending on climate, activity, and health conditions. Overhydration isn’t beneficial and can strain the kidneys—balance is key.
Reference: NKF, 2023.

2. Control Blood Pressure

High blood pressure is one of the top causes of chronic kidney disease (CKD). Aim for a blood pressure below 130/80 mmHg. This often means moderating salt intake, keeping a healthy weight, and following up with your doctor regularly.
Reference: KDIGO Clinical Practice Guidelines, 2021.

3. Manage Blood Sugar

Diabetes damages kidney blood vessels over time. Keep fasting glucose, HbA1c, and lipid levels within target ranges through diet, exercise, and medications if needed.
Reference: American Diabetes Association (ADA) Standards of Care, 2024.

4. Eat a Kidney-Friendly Diet

Limit excessive salt (less than 2,300 mg/day), avoid processed foods, and favor fresh fruits, vegetables, whole grains, and lean proteins. If you have CKD, your doctor may adjust protein, potassium, or phosphorus intake.
Reference: WHO Healthy Diet Guidelines, 2023.

5. Avoid Overuse of NSAIDs

Painkillers like ibuprofen, naproxen, and diclofenac can harm the kidneys, especially with long-term or high-dose use. Use them only when necessary and under medical advice.
Reference: NKF Medication Safety Factsheet, 2023.

6. Stay Active and Maintain a Healthy Weight

Exercise improves circulation, reduces blood pressure, and supports kidney function. Even brisk walking 30 minutes a day helps.
Reference: CDC Physical Activity Guidelines, 2022.

7. Avoid Smoking and Limit Alcohol

Smoking damages kidney blood vessels, while excessive alcohol can dehydrate and harm them. Quitting smoking lowers CKD risk and improves overall health.
Reference: WHO Tobacco and Health Report, 2023.

8. Get Regular Checkups

If you have diabetes, hypertension, obesity, or a family history of kidney disease, get tested yearly for serum creatinine (to estimate GFR) and urine albumin. Early detection can prevent progression.
Reference: KDIGO CKD Screening Recommendations, 2021.

9. Be Cautious with Supplements and Herbal Remedies

Some herbal or “detox” products can be toxic to kidneys. Always verify ingredients and consult a healthcare professional before use.
Reference: U.S. FDA Consumer Update, 2023.

10. Sleep and Stress Management

Poor sleep and chronic stress elevate blood pressure and inflammation, both harmful to kidneys. Aim for 7–8 hours of good-quality sleep per night.
Reference: American Heart Association (AHA), 2023.

Healthy kidneys are quiet workers—if they start making noise, it’s often late in the game. Prevention and early detection are far easier than treatment.